CDK4 and neoplasm: Together these recent findings suggest that shorter intervals of CDK4/6i treatment would, at a minimum, be sufficient to improve the anti-tumor T cell phenotype, and maintain a favorable distribution of effector/regulatory T cell subsets within tumors.